Survey Reports Changes in Pediatric Rheumatology Practice During the COVID-19 Pandemic
A group of rheumatologists and researchers analyzed how the COVID-19 pandemic has affected pediatric rheumatology practice.
A group of rheumatologists and researchers analyzed how the COVID-19 pandemic has affected pediatric rheumatology practice.
The FDA has approved Simponi Aria for the treatment of patients aged 2 years and older with active polyarticular juvenile idiopathic arthritis.
Patients treated with tofacitinib experienced significantly fewer disease flares compared with placebo.
An international panel of pediatric rheumatologists created a new score to address a lack in the 4-item JADAS in quantifying the burden of extra-articular manifestations of juvenile idiopathic arthritis.
Researchers evaluated the use and performance of genomic risk scores for the clinical diagnosis of juvenile idiopathic arthritis.
Severe disease and death appear to be rare among children and young people hospitalized with laboratory-confirmed COVID-19.
Prevalence of SARS-CoV-2 in asymptomatic children linked to incidence of COVID-19 in general population.
Type 2 diabetes may negatively impact bone density around the age of peak bone mass.
HHS issued the amendment in order to increase access to childhood vaccines and decrease the risk of vaccine-preventable disease outbreaks as children return to daycare and school.
Adding corticosteroids to initial IV immunoglobulin may reduce risk for coronary artery abnormalities.